- Previous Close
134.00 - Open
135.00 - Bid --
- Ask --
- Day's Range
135.00 - 135.00 - 52 Week Range
99.00 - 155.00 - Volume
50 - Avg. Volume
2 - Market Cap (intraday)
8.117B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-6.53 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ascendispharma.comRecent News: A71.F
View MorePerformance Overview: A71.F
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: A71.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: A71.F
View MoreValuation Measures
Market Cap
7.77B
Enterprise Value
8.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.49
Price/Book (mrq)
--
Enterprise Value/Revenue
22.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-103.97%
Return on Assets (ttm)
-17.38%
Return on Equity (ttm)
--
Revenue (ttm)
363.64M
Net Income Avi to Common (ttm)
-378.08M
Diluted EPS (ttm)
-6.53
Balance Sheet and Cash Flow
Total Cash (mrq)
559.54M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-200.32M